LEADER 01494nam  2200409   450 
001 9910704779103321
005 20130725065450.0
035   $a(CKB)5470000002443931
035   $a(OCoLC)853659517
035   $a(EXLCZ)995470000002443931
100   $a20130725d2013      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 10$aMedicare $einformation on highest-expenditure Part B drugs : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives /$fstatement of James Cosgrove
210  1$a[Washington, D.C.] :$cUnited States Government Accountability Office,$d2013.
215   $a1 online resource (10 pages)
225 1 $aTestimony ;$vGAO-13-739T
300   $aTitle from title screen (viewed July 18, 2013).
300   $a"For release ... June 28, 2013."
320   $aIncludes bibliographical references.
517   $aMedicare 
606   $aMedicare$xEconomic aspects
606   $aDrugs$xPrices$zUnited States
615  0$aMedicare$xEconomic aspects.
615  0$aDrugs$xPrices
700   $aCosgrove$b James C.$01395889
712 02$aUnited States.$bCongress.$bHouse.$bCommittee on Energy and Commerce.$bSubcommittee on Health,
712 02$aUnited States.$bGovernment Accountability Office,
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910704779103321
996   $aMedicare$93462118
997   $aUNINA